Rapid identification of frequent MLL rearrangements in hematologic malignancies by multiplex RT-PCR in a single assay
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TO THE EDITOR
Andersson et al 1 reported the development of a paired multiplex reverse-transcriptase polymerase chain reaction (PMRT-PCR) for the detection of MLL fusion genes in hematologic malignancies. They described this method as allowing rapid and accurate detection of the clinically relevant fusion genes MLL/AF4, MLL/AF6, MLL/AF9, MLL/AF10, MLL/ELL and MLL/ENL in one single assay. In their multiplex assay they applied two separate primer pairs, for each fusion gene, that were used in two parallel one-step multiplex PCR reactions with 'out-mix' primers and 'in-mix' primers. Thus each sample was tested twice for the presence of a specific MLL fusion gene and the designed out-mixes and in-mixes that produced PCR fragments increased the specificity of the assay. However, a split-out reaction for each case was necessary in a second step to identify the specific fusion genes with corresponding primers.
We had developed in our laboratory a corresponding strategy using PMRT-PCR for the detection of MLL fusion genes but we were able to identify the partner gene only in one single assay. In our protocol we analyzed the frequent fusion genes involved in acute myeloid leukemia (LAM) as AF6, AF9 and ELL and in acute lymphoblastic leukemia (LAL) as AF4 and ENL.
Different mixes could be used in a one-step multiplex PCR reaction. Each mix contained a single 5Ј MLL-specific primer located in e8 (accession number; X83604, 5Ј position; 451, size; 23) in combination with 3Ј primers specific for the different fusion genes analysed. The following 3Ј primers used in the different reaction mixtures had been proposed by Repp et al 2 and by Poirel et al 3 for ELL-specific primers: mix 1 primers P4(AF4), P6(AF6), P8(AF9), P10(ENL) and ELLint(ELL), mix 1bis primer P3(AF4), mix 6bis primer P5(AF6), mix 9bis primer P7(AF9), mix 19bis primers P9(ENL) and ELLext(ELL). The expressed housekeeping gene HPRT (hypoxanthine phosphoribosyltransferase) 4 was co-amplified as internal control in each mix. Three mixs (1, 1bis, 19bis) were designed for identification of the frequent fusion genes of a LAL patient while four mixes (1, 6bis, 9bis, 19bis) were designed for identification of the frequent fusion genes of a LAM patient. Each assay was carried out with negative controls (RT without reverse-transcriptase and RT without RNA template) and with positive controls. The specificity of amplified products was confirmed after hybridization with the specific probe MLL5Јbiot (accession number; X83604, 5Ј position; 478, size; 21). Moreover it was easy to identify either MLL/ENL or MLL/ELL fusion genes with the same mix 19bis because of different sizes of the PCR products. Sequencing of the PCR products were consistent with the fusion of MLL gene and the partner genes identified by our protocol.
In this strategy the screening of the chimeric fusion gene was obtained by using the mix 1 while the identification of the partner In conclusion, our one-step multiplex method allows us to identify rapidly and accurately in only one assay five clinically important chimeric genes involving MLL, while the method reported by Andersson et al needs a second step to specify the fusion gene. Like them we have increased the specificity of our assay by using two sets of primers for each fusion gene and by hybridization with the MLL-specific probe. We also think that the present method may be expanded to include additional fusion genes.
